Further investigations will likely reveal a more comprehensive understanding of the mechanisms underlying the anti-MM effects of the CB-839/panobinostat combination therapy, potentially leading to the discovery of metabolite indicators that can predict the clinical success of GLS inhibitors in MM. The gene discussed is GLS; the disease is Miyoshi myopathy.